ME00024B - Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama - Google Patents
Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinamaInfo
- Publication number
- ME00024B ME00024B MEP-2008-32A MEP200832A ME00024B ME 00024 B ME00024 B ME 00024B ME P200832 A MEP200832 A ME P200832A ME 00024 B ME00024 B ME 00024B
- Authority
- ME
- Montenegro
- Prior art keywords
- modified
- polypeptides
- pharmacokinetic properties
- improved pharmacokinetic
- detected
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 101150048336 Flt1 gene Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
Abstract
Otkriveni su modifikovani himemi polipeptidi sa poboljšanim farmakokinetičkim osobinama. Specifično su otkriveni, modifikovani himemi polipeptidi sa Fltl receptorom, koji su modifikovani na takav način da bi se poboljšao njihov farmakokinetički profil. Takođe su otkriveni postupci dobijanja i korišćenja modifikovanih polipeptida uključujući ali se ne ograničavajući na upotrebu modifikovanih polipeptida da bi se smanjilo ili inhibiralo propuštanje plazme i/ili vaskulame permeabilnosti kod sisara. Otkriveni su modifikovani himemi polipeptidi sa poboljšanim farmakokinetičkim osobinama. Specifično su otkriveni, modifikovani himemi polipeptidi sa Fltl receptorom, koji su modifikovani na takav način da bi se poboljšao njihov farmakokinetički profil. Takođe su otkriveni postupci dobijanja i korišćenja modifikovanih polipeptida uključujući ali se ne ograničavajući na upotrebu modifikovanih polipeptida da bi se smanjilo ili inhibiralo propuštanje plazme i/ili vaskulame permeabilnosti kod sisara.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13813399P | 1999-06-08 | 1999-06-08 | |
PCT/US2000/014142 WO2000075319A1 (en) | 1999-06-08 | 2000-05-23 | Modified chimeric polypeptides with improved pharmacokinetic properties |
Publications (1)
Publication Number | Publication Date |
---|---|
ME00024B true ME00024B (me) | 2010-02-10 |
Family
ID=22480568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-32/08A MEP3208A (xx) | 1999-06-08 | 2000-05-23 | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
MEP-2008-32A ME00024B (me) | 1999-06-08 | 2000-05-23 | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-32/08A MEP3208A (xx) | 1999-06-08 | 2000-05-23 | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
Country Status (33)
Country | Link |
---|---|
EP (2) | EP1183353B1 (me) |
JP (2) | JP4723140B2 (me) |
KR (1) | KR100659477B1 (me) |
CN (3) | CN101433715B (me) |
AT (2) | ATE417928T1 (me) |
AU (2) | AU779303B2 (me) |
BE (1) | BE2013C029I2 (me) |
BR (2) | BR0011407A (me) |
CA (1) | CA2376379C (me) |
CY (2) | CY1108883T1 (me) |
CZ (2) | CZ303656B6 (me) |
DE (2) | DE60019415T2 (me) |
DK (2) | DK1183353T3 (me) |
ES (2) | ES2237429T3 (me) |
FR (1) | FR13C0028I2 (me) |
HK (3) | HK1043388A1 (me) |
HR (1) | HRP20010908B1 (me) |
HU (3) | HU229156B1 (me) |
IL (3) | IL146890A0 (me) |
LT (1) | LTC1183353I2 (me) |
LU (1) | LU92195I2 (me) |
ME (2) | MEP3208A (me) |
MX (1) | MXPA01012630A (me) |
NO (3) | NO330775B1 (me) |
NZ (1) | NZ515913A (me) |
PL (1) | PL208247B1 (me) |
PT (2) | PT1544299E (me) |
RS (1) | RS50073B (me) |
RU (1) | RU2265661C2 (me) |
SK (1) | SK287332B6 (me) |
UA (1) | UA74146C2 (me) |
WO (1) | WO2000075319A1 (me) |
ZA (1) | ZA200110068B (me) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
ATE359300T1 (de) | 2001-01-19 | 2007-05-15 | Ludwig Inst Cancer Res | Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung |
US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
ATE500842T1 (de) | 2002-05-04 | 2011-03-15 | Acorda Therapeutics Inc | Zusammensetzungen und verfahren zur förderung des neuronalen wachstums |
WO2004087206A2 (en) * | 2003-03-28 | 2004-10-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking vegf-mediated activity |
AU2004247025B8 (en) * | 2003-05-16 | 2011-06-30 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of CNS |
MX348062B (es) | 2003-05-16 | 2017-05-26 | Acorda Therapeutics Inc | Mutantes que degradan proteoglicanos para tratamiento del snc. |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
EP1626989A2 (en) * | 2003-05-28 | 2006-02-22 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
US20050112061A1 (en) * | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
MXPA06013345A (es) | 2004-05-18 | 2008-10-31 | Acorda Therapeutics Inc | Metodos para purificar condrointinasa y sus formulaciones estables. |
JP4680997B2 (ja) | 2004-06-08 | 2011-05-11 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管新生を阻害するキメラタンパク質およびその利用 |
AU2005254058A1 (en) * | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for the treatment of human cancer |
WO2006009809A2 (en) * | 2004-06-18 | 2006-01-26 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
EP1771189A2 (en) | 2004-07-30 | 2007-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating type i diabetes by blocking vegf-mediated activity |
DK1804835T3 (da) | 2004-09-13 | 2010-10-11 | Genzyme Corp | Multimere konstruktioner |
FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
CA2995971A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
EP1928490B8 (en) | 2005-09-26 | 2012-10-03 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
JP5489465B2 (ja) † | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Dll4アンタゴニストによって腫瘍増殖を阻害する治療方法 |
FR2895258B1 (fr) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
CN100502945C (zh) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
JP5216002B2 (ja) | 2006-06-16 | 2013-06-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 硝子体内投与に適したvegfアンタゴニスト製剤 |
WO2008042236A2 (en) | 2006-09-29 | 2008-04-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
AU2007307736C1 (en) | 2006-10-10 | 2014-04-10 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
CN101575379B (zh) * | 2008-05-09 | 2012-05-30 | 上海抗体药物国家工程研究中心有限公司 | 可溶性vegfr双功能融合受体、其制备方法及用途 |
KR101698362B1 (ko) | 2008-11-03 | 2017-01-20 | 몰리큘라 파트너스 아게 | Vegf-a 수용체 상호작용을 억제하는 결합 단백질 |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
HUE035554T2 (en) | 2010-08-06 | 2018-05-02 | Genzyme Corp | VEGF antagonist compositions and their uses |
JP6043629B2 (ja) * | 2011-01-07 | 2016-12-14 | 中外製薬株式会社 | 抗体の物性を改善させる方法 |
EP3763379A1 (en) | 2011-01-13 | 2021-01-13 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
CA2857168C (en) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
CN103304668B (zh) * | 2012-03-12 | 2015-10-28 | 江苏健德生物药业有限公司 | Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用 |
EP3646880A1 (en) | 2012-05-07 | 2020-05-06 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
PT2956476T (pt) | 2013-02-18 | 2020-02-21 | Vegenics Pty Ltd | Moléculas de ligação e usos destas |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CN104193828B (zh) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | 同时阻断her2和vegfr信号通路的重组融合蛋白 |
KR20160070164A (ko) | 2013-11-05 | 2016-06-17 | 알러간, 인코포레이티드 | 항-vegf darpin으로 눈의 병태를 치료하는 방법 |
CA2947456C (en) | 2014-05-12 | 2023-03-14 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
DK3170005T3 (da) | 2014-07-18 | 2019-07-08 | Sanofi Sa | Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer |
JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
US20170326106A1 (en) | 2014-12-11 | 2017-11-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
GB201503453D0 (en) | 2015-03-01 | 2015-04-15 | Jain Arjun | Endothelin-1"sponge" |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
WO2017065559A1 (ko) | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Igg fc 도메인을 가지는 융합 단백질의 생산방법 |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
RU2734958C2 (ru) | 2015-11-18 | 2020-10-26 | Формикон Аг | Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf |
BR112018009951A8 (pt) | 2015-11-18 | 2019-02-26 | Sio2 Medical Products Inc | fármaco oftálmico |
BR112018010005A2 (pt) | 2015-11-18 | 2018-11-21 | Formycon Ag | seringa pré-carregada, e, kit |
EP3377101A4 (en) * | 2015-11-19 | 2019-08-07 | Zhuhai Tairuishang Biopharm Ltd. | VEGF BINDING METHODS AND COMPOSITIONS |
KR102261636B1 (ko) | 2015-12-03 | 2021-06-07 | 리제너론 파마슈티칼스 인코포레이티드 | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 |
EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
JPWO2018070390A1 (ja) | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗robo4抗体と他剤を含む組成物 |
CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
WO2018217995A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
JP7097433B2 (ja) | 2017-08-17 | 2022-07-07 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法 |
CN111356471A (zh) | 2017-11-20 | 2020-06-30 | 济世发展生物药业有限公司 | 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途 |
EP4219695A3 (en) * | 2017-11-27 | 2024-01-17 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
PL3716992T3 (pl) | 2017-11-30 | 2022-12-19 | Regeneron Pharmaceuticals, Inc. | Zastosowanie antagonisty vegf do leczenia angiogennych zaburzeń oka |
KR20200097759A (ko) | 2017-12-13 | 2020-08-19 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피 칼럼 베드 지지체를 관리하기 위한 장치 및 시스템, 및 관련 방법 |
WO2019147944A1 (en) * | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disordres using anti-vegf agents |
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
CN111378044B (zh) | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
WO2020229584A1 (en) | 2019-05-16 | 2020-11-19 | Formycon Ag | Method for reducing methionine oxidation in recombinant proteins |
WO2021046070A1 (en) | 2019-09-03 | 2021-03-11 | Amgen Inc. | Injection device for drug delivery and packaging for the injection device |
US20210077645A1 (en) | 2019-09-16 | 2021-03-18 | Amgen Inc. | Method for external sterilization of drug delivery device |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
KR20220104756A (ko) | 2019-11-25 | 2022-07-26 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제 |
WO2021112925A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
WO2021113591A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Vegf mini-traps and methods of use thereof |
JP2023514325A (ja) | 2020-02-24 | 2023-04-05 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌中に使用するための容器及びシステム |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
WO2024029876A1 (ko) * | 2022-08-02 | 2024-02-08 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
-
2000
- 2000-05-23 CA CA002376379A patent/CA2376379C/en not_active Expired - Lifetime
- 2000-05-23 AT AT05001328T patent/ATE417928T1/de active
- 2000-05-23 AU AU50404/00A patent/AU779303B2/en active Active
- 2000-05-23 BR BR0011407-3A patent/BR0011407A/pt not_active IP Right Cessation
- 2000-05-23 NZ NZ515913A patent/NZ515913A/xx not_active IP Right Cessation
- 2000-05-23 PT PT05001328T patent/PT1544299E/pt unknown
- 2000-05-23 EP EP00932721A patent/EP1183353B1/en not_active Expired - Lifetime
- 2000-05-23 CN CN2008101093559A patent/CN101433715B/zh not_active Expired - Lifetime
- 2000-05-23 DK DK00932721T patent/DK1183353T3/da active
- 2000-05-23 WO PCT/US2000/014142 patent/WO2000075319A1/en active Application Filing
- 2000-05-23 CN CNB008115443A patent/CN100523187C/zh not_active Expired - Lifetime
- 2000-05-23 SK SK1752-2001A patent/SK287332B6/sk not_active IP Right Cessation
- 2000-05-23 ME MEP-32/08A patent/MEP3208A/xx unknown
- 2000-05-23 BR BRPI0011407A patent/BRPI0011407B8/pt unknown
- 2000-05-23 AT AT00932721T patent/ATE293164T1/de active
- 2000-05-23 PL PL352246A patent/PL208247B1/pl active Protection Beyond IP Right Term
- 2000-05-23 ES ES00932721T patent/ES2237429T3/es not_active Expired - Lifetime
- 2000-05-23 PT PT00932721T patent/PT1183353E/pt unknown
- 2000-05-23 DK DK05001328T patent/DK1544299T3/da active
- 2000-05-23 MX MXPA01012630A patent/MXPA01012630A/es active IP Right Grant
- 2000-05-23 ME MEP-2008-32A patent/ME00024B/me unknown
- 2000-05-23 DE DE60019415T patent/DE60019415T2/de not_active Expired - Lifetime
- 2000-05-23 HU HU0201515A patent/HU229156B1/hu active Protection Beyond IP Right Term
- 2000-05-23 JP JP2001502582A patent/JP4723140B2/ja not_active Expired - Lifetime
- 2000-05-23 UA UA2001128378A patent/UA74146C2/uk unknown
- 2000-05-23 DE DE60041159T patent/DE60041159D1/de not_active Expired - Lifetime
- 2000-05-23 IL IL14689000A patent/IL146890A0/xx unknown
- 2000-05-23 EP EP05001328A patent/EP1544299B1/en not_active Expired - Lifetime
- 2000-05-23 RU RU2002100071/13A patent/RU2265661C2/ru active Protection Beyond IP Right Term
- 2000-05-23 CN CN201310118971.1A patent/CN103349781B/zh not_active Expired - Lifetime
- 2000-05-23 ES ES05001328T patent/ES2319305T3/es not_active Expired - Lifetime
- 2000-05-23 CZ CZ20100386A patent/CZ303656B6/cs not_active IP Right Cessation
- 2000-05-23 RS YUP-869/01A patent/RS50073B/sr unknown
- 2000-05-23 HU HU1300086A patent/HU230159B1/hu unknown
- 2000-05-23 KR KR1020017015839A patent/KR100659477B1/ko active Protection Beyond IP Right Term
- 2000-05-23 CZ CZ20014387A patent/CZ302689B6/cs unknown
-
2001
- 2001-12-03 IL IL146890A patent/IL146890A/en active Protection Beyond IP Right Term
- 2001-12-06 ZA ZA200110068A patent/ZA200110068B/xx unknown
- 2001-12-07 HR HR20010908A patent/HRP20010908B1/xx not_active IP Right Cessation
- 2001-12-10 NO NO20016036A patent/NO330775B1/no active Protection Beyond IP Right Term
-
2002
- 2002-07-04 HK HK02105009A patent/HK1043388A1/xx not_active IP Right Cessation
-
2005
- 2005-03-31 AU AU2005201365A patent/AU2005201365B2/en not_active Expired
-
2008
- 2008-03-17 IL IL190234A patent/IL190234A0/en not_active IP Right Cessation
-
2009
- 2009-03-16 CY CY20091100288T patent/CY1108883T1/el unknown
- 2009-11-05 HK HK09110323.8A patent/HK1132653A1/xx unknown
-
2010
- 2010-05-06 NO NO20100656A patent/NO332559B1/no not_active IP Right Cessation
- 2010-10-06 JP JP2010226970A patent/JP5273746B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-13 CY CY2013019C patent/CY2013019I2/el unknown
- 2013-05-13 BE BE2013C029C patent/BE2013C029I2/fr unknown
- 2013-05-14 LT LTPA2013009C patent/LTC1183353I2/lt unknown
- 2013-05-14 FR FR13C0028C patent/FR13C0028I2/fr active Active
- 2013-05-14 LU LU92195C patent/LU92195I2/fr unknown
- 2013-05-15 NO NO2013010C patent/NO2013010I1/no unknown
- 2013-09-17 HU HUS1300052C patent/HUS1300052I1/hu unknown
- 2013-11-26 HK HK13113191.5A patent/HK1185798A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME00024B (me) | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama | |
NL7612591A (nl) | Warmte-isolerend samengesteld profiel, alsmede werkwijze en inrichting voor het vervaardigen daarvan. | |
DE60322513D1 (de) | Stabilisierte TNFR-Fc Formulierung mit Arginin | |
DK1242452T3 (da) | Kimære natriuretiske peptider | |
DE69634640D1 (de) | Mutierte alpha-amylase enzyme mit erhöhter stabilität | |
ATE288765T1 (de) | Polypeptidzusammensetzungen mit verbesserter stabilität | |
DK0792288T3 (da) | Konjugater af BDNF og NT-3 med en vandopløselig polymer | |
AU2001291687A1 (en) | Polyammonium-polysiloxane compounds, methods for the production and use thereof | |
DE60044761D1 (de) | Turbinenleitapparat mit Druckausgleich | |
IT1318319B1 (it) | Composizione di gomma, procedimento per produrre la stessa e manicottoutilizzante la composizione di gomma. | |
DE50109995D1 (de) | Membraneinspannung mit Elastizitätsausgleich | |
DE60045020D1 (de) | Alpha-Amylase-Mutanten | |
DE50206079D1 (de) | Transparentes wässriges beschichtungsmittel mit glasmehl | |
CN210140924U (zh) | 一种保温墙 | |
DE29619576U1 (de) | Dichtungsbahnen | |
ATE278077T1 (de) | Verglasung | |
ITTO20010403A0 (it) | Boccola lineare, in particolare per consentire la traslazione di due elementi strutturali. | |
PL128827U1 (pl) | Profil słupka narożnego w ścianie szklanej jednoszybowej | |
NO20033956D0 (no) | Stenter med radioaktivt belegg | |
本多広樹 et al. | The role of high-technology diffusion for sustainable urban development | |
SE9901702D0 (sv) | Gardinskena | |
DE60142049D1 (de) | Stranggiessdüse mit druckausgleich | |
NL193523B (nl) | Beschermingskledij met klemringen ter afdichting in het arm- en beengebied. | |
CN108433327A (zh) | 一种组合式沙滩垫 | |
Elias | Natural slate. |